A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma Interventions:   Drug: IBI318;   Procedure: cTACE;   Drug: placebo Sponsor:   Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials